Lv4
418 积分 2025-10-20 加入
Clinical Utility of a 50% and 30% Decline in Magnetic Resonance Imaging-Proton Density Fat Fraction in Predicting Fibrosis Improvement in Metabolic Dysfunction-Associated Steatohepatitis
5天前
已完结
Semaglutide therapy for metabolic dysfunction–associated steatohepatitis: November 2025 updates to AASLD Practice Guidance
6天前
已完结
Clinical Trial: Semaglutide Versus Placebo in NIT ‐Assessed MASH —A Multicenter Randomised Placebo‐Controlled Trial ( SAMARA )
1个月前
已完结
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
1个月前
已完结
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
1个月前
已完结
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
1个月前
已完结
非酒精性脂肪性肝病治疗研究进展
1个月前
已完结
Hepatic thyroid hormone receptor‐β signalling: Mechanisms and recent advancements in the treatment of metabolic dysfunction‐associated steatohepatitis
1个月前
已完结
Selinexor in multiple myeloma
1个月前
已完结
Quantification of Visceral Fat Using Dual-Energy X-Ray Absorptiometry and Its Reliability According to the Amount of Visceral Fat in Korean Adults
1个月前
已完结
皖公网安备34019202002308
